GLP-1s and Bone Density: Does Ozempic Cause Bone Loss?

By Amanda Boike Fitness

If you're taking Ozempic, Wegovy, or another GLP-1 medication, you've probably heard about the importance of preserving muscle during weight loss. But what about your bones?

Substantial weight loss can affect bone mineral density, particularly in adults who already have an elevated risk of osteoporosis. For women approaching or going through menopause, this question deserves extra attention because declining estrogen levels can also influence how quickly bone is lost.

The research, however, is more nuanced than the claim that Ozempic causes bone loss. Studies have not established that GLP-1 medications directly cause osteoporosis. Some have observed reductions in bone density during medication-assisted weight loss, while larger analyses have not found an overall increase in fractures.

Understanding the distinction can help you make better decisions about exercise, nutrition, and whether a bone-density assessment is appropriate.

What Happens to Bone Density During Weight Loss?

Bone is living tissue. Throughout life, specialized cells remove older bone and replace it with new bone. The balance between these processes determines whether bone mass increases, remains stable, or decreases.

Mechanical loading is one influence on that balance.

When you walk, climb stairs, carry heavy objects, or lift weights, forces travel through your skeleton. Bone responds to repeated mechanical demands, although its adaptations occur much more slowly than improvements in muscular strength.

Body weight also contributes to skeletal loading. Losing a substantial amount of weight reduces the everyday forces acting on certain bones. When weight loss is accompanied by reduced food intake, additional concerns include whether the body receives enough protein, calcium, vitamin D, and total energy. This helps explain why bone loss has been observed during weight-reduction interventions even when GLP-1 medications were not involved. When it comes to GLP-1 bone density, practical question is whether the medication introduces an additional risk beyond the weight loss itself.

Does Ozempic Actually Cause Bone Loss?

Researchers have approached this question through clinical trials, observational studies, and systematic reviews. The findings are not entirely uniform. A 2026 systematic review and meta-analysis by Beaudart and colleagues examined 60 studies involving approximately 1.25 million participants. The analysis included several GLP-1 receptor agonists, as well as tirzepatide, which acts on both GLP-1 and GIP receptors.

When researchers considered the most-adjusted estimates, they found no overall adverse effect on bone mineral density or fracture outcomes. That's reassuring at a population level, but there are important qualifications. Many of the included studies were conducted in people with diabetes rather than specifically in postmenopausal women receiving obesity-treatment doses. Bone and fracture outcomes were not always the primary purpose of the trials. The absence of a significant overall effect therefore does not establish that every individual, medication, dose, or weight-loss circumstance carries the same risk.

What a randomized trial tells us

A particularly useful experiment was published in JAMA Network Open in 2024.

In the randomized trial's bone-health analysis, 195 adults with obesity first completed an eight-week low-calorie diet. They were then assigned to one of four approaches for 52 weeks: liraglutide, exercise, both treatments, or placebo.

The exercise intervention combined cycling, circuit-based strength work, and other moderate-to-vigorous physical activity.

Participants receiving liraglutide alone experienced greater decreases in hip and lumbar-spine bone mineral density than those in the exercise group. Meanwhile, the combined exercise-and-medication group achieved the greatest weight loss without significantly greater losses in those bone-density measures compared with placebo.

The finding supports the potential value of exercise during medication-assisted weight reduction. However, it would be inaccurate to conclude that this trial proved a particular home strength routine prevents Ozempic-related osteoporosis. Researchers studied liraglutide rather than semaglutide, used a mixed exercise program, and measured bone density rather than long-term fracture prevention.

Taken together, the research suggests that monitoring bone health during substantial weight loss is sensible, especially for women who already have relevant risk factors. It does not justify assuming that medication use alone means bone damage is occurring. For a broader explanation of body-composition changes during treatment, see our guide to GLP-1 muscle loss and body changes.

Why Menopause Makes Bone Health Particularly Relevant

Estrogen helps regulate bone remodeling. As estrogen levels decline through the menopause transition, bone breakdown can begin to exceed bone formation more rapidly.

Some women experience a relatively pronounced decrease in bone density around their final menstrual period. This process can occur independently of GLP-1 medication use. If a woman is also losing a substantial amount of weight, the changes deserve consideration together rather than being attributed automatically to one cause.

There is also an important difference between osteopenia and osteoporosis.

Osteopenia refers to bone density below the expected range for healthy young adults, while osteoporosis is a condition associated with significantly weakened bones and increased fracture risk. Clinicians consider DXA measurements, previous fractures, age, and other risk factors when deciding whether treatment is appropriate. A change in body weight or muscle definition cannot tell you whether your bones have become weaker.

What Kind of Exercise Supports Bone Strength?

One of the most useful distinctions is between exercise that strengthens muscle and exercise that provides enough mechanical loading to stimulate bone adaptation.

The two often overlap, but they are not identical.

Progressive resistance training

Strength training creates forces through the muscles, tendons, and bones. As resistance becomes more challenging, the skeleton experiences mechanical demands beyond those of many everyday activities. Exercises such as squats, hip hinges, rows, presses, and loaded carries can help build strength while loading different parts of the body.

A 2022 UK consensus statement on exercise for osteoporosis recommends progressive resistance training two or three days per week for people with osteoporosis, with exercise selection and intensity adjusted to individual ability.

The authors describe progressing toward loads that can be lifted approximately eight to twelve times, with up to three sets per exercise.

These are longer-term training recommendations, not a requirement to begin immediately with heavy weights. Someone new to resistance training may first need lighter resistance to learn movement patterns and assess tolerance.

For practical examples, our article on low-impact strength exercises explains how support, exercise position, and resistance can be adjusted without eliminating muscular effort.

Impact and weight-bearing exercise

Activities involving impact can provide a different stimulus. Brisk walking, jogging, hopping, and jumping place forces through the skeleton. Their bone-building potential depends on the magnitude, direction, and novelty of those forces.

For someone without an elevated fracture risk, gradually introducing appropriate impact activities may complement resistance training. For someone with osteoporosis, particularly a history of vertebral fractures, the decision is different.

The UK consensus recommends that people with vertebral fractures or multiple low-trauma fractures generally limit impact to levels comparable to brisk walking unless given individualized professional guidance. A low-impact strength program can still provide valuable muscular loading and physical-function benefits. However, avoiding all impact should not automatically be presented as the optimal strategy for maximizing bone density in every person.

Can You Strength Train If You Have Osteoporosis?

Often, yes. In fact, appropriately selected resistance exercise is recommended for many people with osteoporosis. The starting point depends on fracture history, spinal health, balance, previous training experience, and medical recommendations.

A supported squat, for example, may allow someone to train the thighs while using a stable chair to manage balance. A standing hip hinge can strengthen the posterior chain while reinforcing control through the hips. However, people with vertebral fractures or substantial fracture risk may need to modify exercises involving repeated, sustained, or heavily loaded spinal flexion.

A BoneFit certified personal trainer or qualified medical professional can help determine appropriate loading and movement choices. This is particularly useful when someone wants to progress beyond gentle exercise but isn't sure which activities are reasonable.

Nutrition Matters Alongside Exercise

Medication-related appetite changes can make adequate food intake more challenging. The 2025 joint advisory on nutritional priorities during GLP-1 therapy emphasizes dietary adequacy, resistance training, and attention to muscle and bone health during treatment. For bone health, calcium and vitamin D are particularly relevant. The Bone Health & Osteoporosis Foundation recommends a total calcium intake of 1,200 mg daily for women aged 51 and older, including food and supplements. Needs differ for younger adults and people with particular medical conditions. Calcium-rich foods include yogurt, milk, calcium-fortified alternatives, calcium-set tofu, and certain canned fish with edible bones. Vitamin D supports calcium absorption, but supplementation should reflect individual risk, dietary intake, and medical advice rather than assuming larger doses are better.

Protein also supports the maintenance and repair of muscle tissue that helps produce skeletal loading. During active weight reduction, the joint advisory discusses higher proposed protein intakes than the general adult RDA, while emphasizing that individual requirements vary. If reduced appetite regularly makes it difficult to eat enough, a registered dietitian familiar with GLP-1 treatment may be helpful.

Should You Get a Bone Density Scan While Taking a GLP-1?

A DXA scan measures bone mineral density, usually at the hip and lumbar spine.

It is not the same as simply tracking body composition or noticing a change in physical appearance.

According to the 2025 U.S. Preventive Services Task Force recommendations, osteoporosis screening is recommended for women aged 65 and older. Screening is also recommended for postmenopausal women younger than 65 who have an increased fracture risk based on clinical assessment.

Relevant factors can include previous fractures, low body weight, parental hip fracture history, smoking, and certain medical conditions or medications.

GLP-1 use alone is not currently established as a universal indication for early DXA screening.

Still, discussing bone health with your clinician is reasonable if you're losing substantial weight and have other risk factors, particularly during or after menopause. A scan can help answer a question that exercise performance and scale weight cannot.

Building Strength While Protecting Your Long-Term Health

Bone health is shaped by more than one variable. Menopause, body weight, nutrition, physical activity, medications, and individual medical history can all contribute. The available evidence does not support assuming that Ozempic inevitably weakens bones. At the same time, substantial weight loss is a good opportunity to reconsider whether your training provides enough resistance to maintain strength.

For women who want help organizing that work, ABF Online provides guided, low-impact strength sessions with two-, three-, and four-day weekly plans. The workouts emphasize controlled resistance and exercise positioning using simple equipment at home.

The program can help make regular muscle-strengthening work more manageable. It is not a treatment for osteoporosis or a replacement for individualized bone-health recommendations.

References

1. Beaudart C, Malréchauffé Y, van Heden S, et al. (2026). GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs, 86, 1661–1691.

2. Jensen SBK, Sørensen V, Sandsdal RM, et al. (2024). Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Network Open, 7(6), e2416775.

3. Brooke-Wavell K, Skelton DA, Barker KL, et al. (2022). Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. British Journal of Sports Medicine, 56, 837–846.

4. Mozaffarian D, Agarwal M, Aggarwal M, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity. Obesity, 33, 1475–1503.

5. U.S. Preventive Services Task Force. (2025). Osteoporosis to Prevent Fractures: Screening. Clinical recommendation.

6. Bone Health & Osteoporosis Foundation. Calcium/Vitamin D Requirements, Recommended Foods & Supplements. Patient guidance.